Skip to Main Content
Principal Investigator
Tanya Rajabi
Semmelweis University
Position Title
Visiting Scholar
About this CDAS Project
NLST (Learn more about this study)
Project ID
Initial CDAS Request Approval
Oct 11, 2022
Comparative analysis of the cost-effectiveness and implementation of lung cancer screening with LDCT in the US and EU
Trials have proven that LDCT screening for lung cancer can reduce lung cancer mortality. Yet, questions remain on routine screening's cost-effectiveness and best implementation practices. The EU guidelines and processes for screening vary from those in the US. Thus, we believe that conducting a comprehensive comparative analysis of lung cancer LDCT screening strategies between the US and EU would provide insight on methods for improving its cost-effectiveness and implementation in both jurisdictions.
More specifically, a Markov cohort model depicting patient screening pathways and assessing cost-effectiveness has been created at Semmelweis University. We propose to update this model with the data from the NLST. Doing so will allow for the comparison of the implementation and cost-effectiveness of screening strategies between the US and EU.

1. Assess the cost-effectiveness of various lung cancer screening strategies.
2. Compare cost-effectiveness of strategies employed by the US and EU to identify both clinically efficient and cost-effective screening practices.


Zoltan Voko (MD, MSc, PhD, DSC), Semmelweis University Center for Health Technology Assessment
Balazs Nagy (MSc, PhD, DrHabil), Semmelweis University Center for Health Technology Assessment